Cover Image
市場調查報告書

抗癲癇藥的全球市場分析、預測:第1代藥、第2代藥、第3代藥、Vimpat、Keppra、Briviact、Lamictal、Potiga/Trobalt、Lyrica、Neurontin

Global Anti-Epilepsy Drugs Market Forecast 2017-2027: First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin

出版商 Visiongain Ltd 商品編碼 524861
出版日期 內容資訊 英文 145 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗癲癇藥的全球市場分析、預測:第1代藥、第2代藥、第3代藥、Vimpat、Keppra、Briviact、Lamictal、Potiga/Trobalt、Lyrica、Neurontin Global Anti-Epilepsy Drugs Market Forecast 2017-2027: First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin
出版日期: 2017年05月12日 內容資訊: 英文 145 Pages
簡介

本報告提供全球抗癲癇藥的市場調查,癲癇及癲癇治療概要,抗癲癇藥市場的各種影響因素及市場趨勢分析,主要企業及主要藥物概要,主要各地區、國家的市場成長預測,價格、償付趨勢,有前途的開發平台分子等彙整資料。

第1章 報告概要

第2章 簡介:癲癇

  • 所謂發作
  • 所謂癲癇重積狀態
  • 癲癇症候群
  • 風險要素
  • 併發症
  • 診斷
  • 流行病學
  • 身體、經濟上的負擔
  • 治療方法
    • 藥物療法
    • 心理的介入
    • 飲食習慣的改善
    • 迷走神經刺激 (VNS)
    • 癲癇手術
    • 腦深部刺激 (DBS)
    • RNS (Responsive. Neurostimulation System)

第3章 簡介:抗癲癇藥市場

  • 市場定義、範圍
  • 市場促進因素、課題、趨勢

第4章 全球抗癲癇藥市場

  • 市場預測
  • 市場預測:各世代
    • 第1代
    • 第2代
    • 第3代
    • 其他

第5章 主要企業

  • 市場佔有率:到目前為止的變化
  • 目前市場的領導者
    • UCB
      • Vimpat
      • Keppra
      • Briviact
    • GlaxoSmithKline
      • Lamictal
      • Potiga / Trobalt
    • Pfizer
      • Lyrica
      • Neurontin

第6章 主要國家市場預測

  • 市場成果:各地區明細
  • 市場預測:各地區
  • 美國
  • 歐盟5國
  • 金磚四國
  • 日本
  • 其他

第7章 價格、償付:概要

  • NICE
  • SMC
  • HAS
  • 加拿大
  • 義大利
  • 美國
  • 澳洲
  • G-BA/IQWIG

第8章 有潛力開發平台分子

  • 開發平台整體趨勢、有希望候補分子
    • Everolimus
    • Lyrica Controlled-release
    • Briviact
    • Vimpat
    • E2007
    • SAGE-547
    • Epidiolex
    • Cenobamate
    • ZX008
    • Ganaxolone
    • Immunoglobulin, normal (human)
    • USL261
    • Alprazolam
    • Ataluren
    • GWP42006
    • PF-062372865
    • UCB-0942 and UCB-3491
    • BGG-492
    • PRX00023
  • 新的作用機制

第9章 總論

圖表

目錄
Product Code: PHA0193

global anti-epilepsy drugs market is expected to grow at a CAGR of 3.8% in the first half of the forecast period and CAGR of 5.0% in the second half of the forecast period. The market is estimated at $4.3bn in 2016 and $6.9bn in 2027.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 145-page report you will receive 100 charts - all unavailable elsewhere.

The 145-page report provides clear detailed insight into the global anti-epilepsy drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Anti-Epilepsy Drugs Market forecasts from 2017-2027
  • Along with revenue prediction for the overall world market for anti-epilepsy drugs, our investigation shows forecasts to 2027 for the leading submarkets:
    • First-generation Drugs
    • Second-generation Drugs
    • Third-generation Drugs
    • Others
  • This report also discusses the leading anti-epilepsy drugs:
    • Vimpat
    • Keppra
    • Briviact
    • Lamictal
    • Potiga/Trobalt
    • Lyrica
    • Neurontin
  • Our analyses show individual revenue forecasts to 2027 for these regional markets:
    • US
    • Japan
    • EU5
    • BRIC
    • RoW
  • This report provides historical and forecast of epilepsy prevalence in the US, Japan, France, Germany, Spain, Italy, and the UK
  • This report covers pricing and reimbursement overview of the anti-epilepsy drugs market
  • This report discusses selected pipeline molecules which are under development for the treatment of epilepsy
  • Our study also identifies and discusses the leading companies in the anti-epilepsy drugs market
  • Our study discusses drivers, challenges, and trends of the anti-epilepsy drugs market from 2016

Visiongain's study is intended for anyone requiring commercial analyses for the anti-epilepsy drugs market. You find data, trends and predictions.

Buy our report today Global Anti-Epilepsy Drugs Market Forecast 2017-2027: First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Why You Should Read This Report
  • 1.2. How This Report Delivers
  • 1.3. Key Questions Answered by This Analytical Report
  • 1.4. Who is This Report For?
  • 1.5. Methodology
    • 1.5.1. Primary Research
    • 1.5.2. Secondary Research
    • 1.5.3. Market Evaluation & Forecasting Methodology
  • 1.6. Frequently Asked Questions (FAQ)
  • 1.7. Associated Visiongain Reports
  • 1.8. About Visiongain

2. Introduction to Epilepsy

  • 2.1. What are Seizures?
  • 2.2. What is status epilepticus?
    • 2.2.1. Types of Seizures
      • 2.2.1.1. Onset of Seizures
      • 2.2.1.2. Level of Awareness
      • 2.2.1.3. Presence or Absence of Motor Symptoms
  • 2.3. Epilepsy Syndrome
  • 2.4. What Are the Risk Factors for Epilepsy?
    • 2.4.1. Age
    • 2.4.2. Head injuries
    • 2.4.3. Family History
    • 2.4.4. Childhood Seizures
    • 2.4.5. Infections
    • 2.4.6. Dementia and Vascular Diseases
    • 2.4.7. Administration of Drugs
  • 2.5. What Are the Various Complications Associated with Epilepsy?
    • 2.5.1. Increased Likelihood of Road Accidents
    • 2.5.2. Increased Risk of Falls and Drowning while Swimming
    • 2.5.3. Complications during Pregnancy
    • 2.5.4. Impairment of Mental Health and Social Stigma Associated with the Disease
    • 2.5.5. Status Epilepticus
    • 2.5.6. Sudden Unexplained Death in Epilepsy (SUDEP)
  • 2.6. Diagnosis of Epilepsy
    • 2.6.1.1. Electroencephalogram (EEG)
    • 2.6.1.2. Neuroimaging
    • 2.6.1.3. Other Tests
    • 2.6.1.4. Neuropsychological Assessment
  • 2.7. Epidemiology of Epilepsy
    • 2.7.1. Incidence
    • 2.7.2. Prevalence
      • 2.7.2.1. Epidemiology by Country
      • 2.7.2.2. Historical Prevalence in G7 Markets
      • 2.7.2.3. Forecast of Epilepsy in G7 Markets 2016-2027
  • 2.8. Humanistic and Economic Burden
    • 2.8.1. Mortality
      • 2.8.1.1. Mortality in the US
      • 2.8.1.2. Mortality in the UK
    • 2.8.2. HRQoL
    • 2.8.3. Economic Impact
      • 2.8.3.1. Direct and Indirect Costs of Caregiving
  • 2.9. Epilepsy: Treatment
    • 2.9.1. Pharmacotherapy
    • 2.9.2. Psychological Interventions
    • 2.9.3. Dietary Modifications
    • 2.9.4. Vagus Nerve Stimulation (VNS)
    • 2.9.5. Epilepsy Surgery
    • 2.9.6. Deep Brain Stimulation (DBS)
    • 2.9.7. Responsive Neurostimulation System (RNS)

3. Introduction to the Anti-Epilepsy Drugs Market

  • 3.1. Market Definition and Scope
  • 3.2. Market Drivers, Challenges, and Trends
    • 3.2.1. Market Drivers
      • 3.2.1.1. Unmet Medical Need
      • 3.2.1.2. Increase in Patient Population
      • 3.2.1.3. Research Funding and Awareness
    • 3.2.2. Market Challenges
      • 3.2.2.1. Market Entry of Generic Drugs
      • 3.2.2.2. Social Stigma Associated with Neurological Disorders
    • 3.2.3. Market Trends
      • 3.2.3.1. Reformulation and Indication Expansion
      • 3.2.3.2. Emergence of New-generation of AEDs

4. Global Anti-Epilepsy Drugs Market 2016

  • 4.1. Global Anti-Epilepsy Drugs Market Forecast 2017-2027
  • 4.1. Market Segmentation by Generation of Drugs
    • 4.1.1. Global Anti-Epilepsy Drugs Submarkets Forecast 2017-2027
      • 4.1.1.1. Global Anti-Epilepsy First Generation Drugs Market Forecast 2017-2027
      • 4.1.1.2. Global Anti-Epilepsy Second Generation Drugs Market Forecast 2017-2027
      • 4.1.1.3. Global Anti-Epilepsy Third Generation Drugs Market Forecast 2017-2027
      • 4.1.1.4. Global Anti-Epilepsy Other Drugs Market Forecast 2017-2027

5. Global Anti-Epilepsy Drugs - Market Players

  • 5.1. Historical Market Share
  • 5.2. Current Market Leaders
    • 5.2.1. UCB
      • 5.2.1.1. Vimpat
      • 5.2.1.2. Keppra
      • 5.2.1.3. Briviact
    • 5.2.2. GlaxoSmithKline
      • 5.2.2.1. Lamictal
      • 5.2.2.2. Potiga / Trobalt
    • 5.2.3. Pfizer
      • 5.2.3.1. Lyrica
      • 5.2.3.2. Neurontin

6. Leading National Markets Forecast 2017-2027

  • 6.1. Geographical Breakdown of Global Anti-Epilepsy Drugs Market, 2016
  • 6.2. Anti-Epilepsy Drugs Market Forecast by Region 2017-2027
  • 6.3. Anti-Epilepsy Drugs Market in the US, 2016
    • 6.3.1. Market Forecast of the US, 2017-2027
  • 6.4. Anti-Epilepsy Drugs Market in EU5, 2016
    • 6.4.1. Market Forecast of EU5, 2017-2027
  • 6.5. Anti-Epilepsy Drugs Market in the BRIC, 2016
    • 6.5.1. Market Forecast of the BRIC, 2017-2027
  • 6.6. Anti-Epilepsy Drugs Market in Japan, 2016
    • 6.6.1. Market Forecast of the Japan, 2017-2027
  • 6.7. Anti-Epilepsy Drugs Market in RoW, 2016
    • 6.7.1. Market Forecast of the RoW, 2017-2027

7. Pricing and Reimbursement Overview

  • 7.1. NICE
  • 7.2. SMC
  • 7.3. HAS
  • 7.4. Canada
  • 7.5. Italy
  • 7.6. United States
  • 7.7. Australia
  • 7.8. G-BA/IQWIG

8. Active Pipeline Molecules

  • 8.1. Overall Pipeline Status and Promising Candidates
    • 8.1.1. Everolimus
    • 8.1.2. Lyrica Controlled-release
    • 8.1.3. Briviact
    • 8.1.4. Vimpat
    • 8.1.5. E2007
    • 8.1.6. SAGE-547
    • 8.1.7. Epidiolex
    • 8.1.8. Cenobamate
    • 8.1.9. ZX008
    • 8.1.10. Ganaxolone
    • 8.1.11. Immunoglobulin, normal (human)
    • 8.1.12. USL261
    • 8.1.13. Alprazolam
    • 8.1.14. Ataluren
    • 8.1.15. GWP42006
    • 8.1.16. PF-062372865
    • 8.1.17. UCB-0942 and UCB-3491
    • 8.1.18. BGG-492
    • 8.1.19. PRX00023
  • 8.2. Novel Mechanism of Action

9. Conclusions

  • Glossary
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 1.1 Example of Global Anti-Epilepsy Drugs Market by Regional Market Forecast 2017-2027 ($m, AGR %, Cumulative)
  • Table 2.1 Type of Focal Seizures
  • Table 2.2 Type of Unknown-onset Seizures
  • Table 2.3 Prevalence of Epilepsy, all ages, all types, rates per 1,000 population per year
  • Table 2.4 Diagnosed Prevalence (absolute cases) of Epilepsy in G7 Markets, 2016
  • Table 2.5 Forecast of Diagnosed Prevalence of Epilepsy in G7 Markets: AGR (%), CAGR (%), 2016-2027
  • Table 2.6 Forecast of Diagnosed Prevalence of Epilepsy in the US: AGR (%), CAGR (%), 2016-2027
  • Table 2.7 Forecast of Diagnosed Prevalence of Epilepsy in France: AGR (%), CAGR (%), 2016-2027
  • Table 2.8 Forecast of Diagnosed Prevalence of Epilepsy in Germany: AGR (%), CAGR (%), 2016-2027
  • Table 2.9 Forecast of Diagnosed Prevalence of Epilepsy in the UK: AGR (%), CAGR (%), 2016-2027
  • Table 2.10 Forecast of Diagnosed Prevalence of Epilepsy in Italy: AGR (%), CAGR (%), 2016-2027
  • Table 2.11 Forecast of Diagnosed Prevalence of Epilepsy in Spain: AGR (%), CAGR (%), 2016-2027
  • Table 2.12 Forecast of Diagnosed Prevalence of Epilepsy in Japan: AGR (%), CAGR (%), 2016-2027
  • Table 2.13 Healthcare Utilization Rates by Caregivers of Individuals Suffering from Epilepsy vs General Population
  • Table 2.14 Direct and Indirect Costs for the General Population and Caregivers of Persons with Epilepsy (in US$)
  • Table 4.1 Global Anti-Epilepsy Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.2 List of some of the Approved AEDs
  • Table 4.3 Global Anti-Epilepsy Drugs Markets by Segmentation: Revenue ($m), and Market Share (%), 2016
  • Table 4.4 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.5 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs 2016-2027: AGR (%)
  • Table 4.6 Global Anti-Epilepsy First Generation Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.7 Global Anti-Epilepsy Second Generation Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.8 Global Anti-Epilepsy Third Generation Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.9 Global Anti-Epilepsy Other Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.1 Product Portfolio of UCB
  • Table 5.2 Vimpat Key Milestones
  • Table 5.3 Keppra / Keppra XR Key Milestones
  • Table 5.4 Briviact Key Milestones
  • Table 5.5 Product Portfolio of Pfizer
  • Table 6.1 Anti-Epilepsy Drugs Market by Region: Revenue ($m), and Market Share (%), 2016
  • Table 6.2 Anti-Epilepsy Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2016-2027
  • Table 6.3 Anti-Epilepsy Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.4 Anti-Epilepsy Drugs Market Forecast in EU5 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.5 Anti-Epilepsy Drugs Market Forecast in BRIC 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.6 Anti-Epilepsy Drugs Market Forecast in Japan 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.7 Anti-Epilepsy Drugs Market Forecast in RoW 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 8.1 Active Pipeline Molecules under Development for Treating Epilepsy

List of Figures

  • Figure 1.1 Example of Global Anti-Epilepsy Drugs Market by Regional Market Share Forecast 2017, 2022, 2027(% Share)
  • Figure 2.1 Types of Generalized Seizures
  • Figure 2.2 Diagnosed Prevalence (absolute cases) of Epilepsy in G7 Markets, 2016
  • Figure 2.3 Diagnosed Prevalence (%) of Epilepsy in G7 Markets, 2016
  • Figure 2. 4 Historical Prevalence of Epilepsy in G7 Markets: CAGR (%), 2011-2015
  • Figure 2.5. Historical Diagnosed Prevalence of Epilepsy in G7 Markets: Share (%) of Absolute cases, 2011-2015
  • Figure 2.6 Forecast of Diagnosed Prevalence of Epilepsy in the US: AGR (%), CAGR (%), 2016-2027
  • Figure 2.7 Forecast of Diagnosed Prevalence of Epilepsy in France: AGR (%), CAGR (%), 2016-2027
  • Figure 2.8 Forecast of Diagnosed Prevalence of Epilepsy in Germany: AGR (%), CAGR (%), 2016-2027
  • Figure 2.9 Forecast of Diagnosed Prevalence of Epilepsy in the UK: AGR (%), CAGR (%), 2016-2027
  • Figure 2.10 Forecast of Diagnosed Prevalence of Epilepsy in Italy: AGR (%), CAGR (%), 2016-2027
  • Figure 2.11 Forecast of Diagnosed Prevalence of Epilepsy in Spain: AGR (%), CAGR (%), 2016-2027
  • Figure 2.12 Forecast of Diagnosed Prevalence of Epilepsy in Japan: AGR (%), CAGR (%), 2016-2027
  • Figure 2.13 Epilepsy and Status Epilepticus Related Deaths in the US, 2015
  • Figure 2.14 Epilepsy and Status Epilepticus Related Deaths in the US, 2013 - 2015
  • Figure 2.15 Epilepsy and Status Epilepticus Related Deaths in the UK, 2015
  • Figure 2.16 Epilepsy Related Deaths in the UK, 2013 - 2015
  • Figure 2.17 Percentage of Adults with and Without Epilepsy Who Have Difficulty Getting Health Care
  • Figure 2.18Treatment Algorithm of Epilepsy using Pharmacotherapies
  • Figure 2.19 Pharmacotherapy for Seizures
  • Figure 2.20Treatment Algorithm of Status Epilepticus using Pharmacotherapies
  • Figure 4.1 Global Anti-Epilepsy Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.2: Epilepsy Market Segmentation by Generation of Drugs
  • Figure 4.3 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs: Revenue ($m), 2016
  • Figure 4.4 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs: Market Share (%), 2016
  • Figure 4.5 Global Anti-Epilepsy Drugs Market by Generation of Drugs 2016-2027: Revenue ($m), Global AGR (%)
  • Figure 4.6 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs: Revenue ($m), CAGR (%), 2016 & 2027
  • Figure 4.7 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs 2016-2027: AGR (%)
  • Figure 4.8 Global Anti-Epilepsy First Generation Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.9 Global Anti-Epilepsy Second Generation Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.10 Global Anti-Epilepsy Third Generation Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.11 Global Anti-Epilepsy Other Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 5.1 Market Share of AEDs, in 2008
  • Figure 5.2 Vimpat Revenue 2011-2016 (US$ million)
  • Figure 5.3 Vimpat Sales by Geographical Segmentation, 2016
  • Figure 5.4 Vimpat Forecasted Revenue 2017-2022 (US$ million)
  • Figure 5.5 Market Growth of Vimpat in the US and EU (in 2016)
  • Figure 5.6 Keppra/Keppra XR Revenue 2011-2016 (US$ million)
  • Figure 5.7 Keppra/Keppra XR Sales by Geographical Segmentation 2016
  • Figure 5.8 Keppra/Keppra XR Forecasted Revenue 2017-2022 (US$ million)
  • Figure 5.9 Market Growth of Keppra/Keppra XR in the US and EU (in 2016)
  • Figure 5.10 Briviact Sales by Geographical Segmentation 2016
  • Figure 5.11 Briviact Forecasted Revenue 2017-2022 (US$ million)
  • Figure 5.12 Lamictal Revenue 2011-2016 (US$ million)
  • Figure 5.13 Lamictal Sales by Geographical Segmentation 2016
  • Figure 5.14 Lyrica Revenue 2011-2016 (US$ million)
  • Figure 5.15 Neurontin Revenue 2011-2016 (US$ million)
  • Figure 6.1 Anti-Epilepsy Drugs Market Segmentation by Region/Country
  • Figure 6.2 Anti-Epilepsy Drugs Market by Region: Revenue ($m)
  • Figure 6.3 Anti-Epilepsy Drugs Market by Region: Market Share 2016 (%)
  • Figure 6.4 Global Anti-Epilepsy Drugs Market in the US: Market Share (%), 2016
  • Figure 6.5 Anti-Epilepsy Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%)
  • Figure 6.6 Anti-Epilepsy Drugs Market in the EU5: Market Share (%), 2016
  • Figure 6.7 Anti-Epilepsy Drugs Market Forecast in EU5 2016-2027: Revenue ($m), AGR (%)
  • Figure 6.8 Anti-Epilepsy Drugs Market in BRIC: Market Share (%), 2016
  • Figure 6.9 Anti-Epilepsy Drugs Market Forecast in BRIC 2016-2027: Revenue ($m), AGR (%)
  • Figure 6.10 Anti-Epilepsy Drugs Market in Japan: Market Share (%), 2016
  • Figure 6.11 Anti-Epilepsy Drugs Market Forecast in Japan 2016-2027: Revenue ($m), AGR (%)
  • Figure 6.12 Anti-Epilepsy Drugs Market Forecast in RoW 2016-2027: Revenue ($m), AGR (%)
  • Figure 8.1 Share of Pipeline Molecules by Phase of Development
  • Figure 8.2 Status of Patent Protection of Afinitor (excludes patent on cancer indications
  • Figure 9.1 Global Anti-Epilepsy Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 9.2 Anti-Epilepsy Drugs Market by Region: Revenue ($m)

Companies Listed

  • Abide Therapeutics
  • Advicenne Pharma SA
  • Alexza Pharmaceuticals
  • American Epilepsy Society
  • Argentum Pharmaceuticals
  • Biscayne Neurotherapeutics
  • Canadian Agency for Drugs and Technologies in Health (CADTH)
  • Catalyst Pharmaceuticals
  • Centers for Disease Control (CDC)
  • Eisai
  • European Medicines Agency (EMA)
  • Food and Drug Administration (FDA)
  • GlaxoSmithKline (GSK)
  • Grifols S.A.
  • GW Pharmaceuticals
  • International League Against Epilepsy (ILAE)
  • Italian Medicines Agency (AIFA)
  • Janssen Pharmaceuticals
  • Japanese Ministry of Health, Labour and Welfare (MHLW)
  • Marinus Pharmaceuticals
  • National Institute of Neurological Disorders and Stroke
  • Novartis
  • Otsuka Pharmaceuticals
  • Pfizer
  • Pharmaceutical Benefits Advisory Committee (PBAC)
  • Proximagen
  • PTC Therapeutics
  • Roche
  • Sage Therapeutics
  • Sanofi
  • Scottish Medicines Consortium (SMC)
  • SK Biopharmaceuticals
  • Takeda
  • The National Institute for Health and Care Excellence (NICE)
  • UCB
  • Upsher-Smith Laboratories
  • World Health Organization (WHO)
  • Zogenix
Back to Top